SARS-CoV-2 S2 ORF Mammalian
To Order Contact us: stephen@expresspharmapulse.com
SARS-CoV-2 Spike S2 Peptide |
|||
9123P | ProSci | 0.05 mg | EUR 235.5 |
Description: (CT) SARS-CoV-2 Spike peptide |
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
|||
79952-2 | BPS Bioscience | 10 mg | EUR 3460 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag |
|||
E80027 | EpiGentek |
|
|
Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial |
|||
E80028 | EpiGentek |
|
|
Spike S2, Fc-Tag (SARS-CoV-2) |
|||
100895-1 | BPS Bioscience | 100 µg | EUR 700 |
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa. |
Spike (SARS-CoV-2) Lentivirus |
|||
78010-2 | BPS Bioscience | 500 µl x 2 | EUR 2095 |
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_ |
3CL Protease (SARS-CoV-2) |
|||
100823-2 | BPS Bioscience | 500 µg_x000D_ | EUR 3360 |
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa. |
Spike Trimer (S1+S2) (B.1.351 Variant), His-Tag (SARS-CoV-2) |
|||
510333-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 South African Variant B.1.351 and contains mutations K417N, E484K and N501Y. It also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification._x000D_ |
Spike Trimer (S1+S2) (B.1.1.7 Variant), His-Tag (SARS-CoV-2) |
|||
510334-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 United Kingdom Variant B.1.1.7. It contains mutations N501Y, A570D, D614G, P681H, T716I, S982A, D1118; deletions: 21765:6 (69-70HV), 21991:3 (44Y). This construct also contains a C-terminal His tag. Note that the expected MW of the S1+S2 monomer is 136kDa. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification. |
Spike Trimer (S1+S2) (K417T, E484K, N501Y), His- Tag (SARS-CoV-2) |
|||
100988-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein contains three mutations: K417T, E484K and N501Y that have been found in emerging SARS-CoV-2 Variants of Concern and may lead to higher transmissibility and infectivity. This mutant Spike Trimer will be useful for structure-function studies, testing of neutralizing antibodies, or antibody and drug screening. _x000D_The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ?90% pure following affinity purification. |
Spike Trimer (S1+S2) (P.1 Variant), His-Tag (SARS-CoV-2) |
|||
100989-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV2 Variant P.1 originally discovered in Brazil and contains 11 mutations in addition to 682RRAR685>A, K986P and V987P, as listed below. The construct also contains a C-terminal His-tag. Note that the expected MW of the S1+S2 monomer is 136kDa but migrates at a higher MW in SDS-PAGE due to glycosylation. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification. |
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag |
|||
E80024 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion |
|||
E80026 | EpiGentek |
|
|
Spike Trimer (S1+S2) (B.1.617.1, Kappa Variant), His-Tag (SARS-CoV-2) |
|||
101144-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits and encompassing amino acids 16-1213. This protein corresponds to SARS-CoV-2 Variant B.1.617.1 also known as variant Kappa originally identified in India, and contains mutations G142D, E154K, L452R, E484Q, D614G, P681R and Q1071H. The construct also contains mutations 682RRAR685>A, K986P and V987P, and a T4 trimerization domain followed by a His-tag (6xHis) in C-terminal. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (XBB, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101660-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag |
|||
E80021 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag |
|||
E80023 | EpiGentek |
|
|
PLPro, His-tag (SARS-CoV-2) |
|||
100735-2 | BPS Bioscience | 1 mg | EUR 3000 |
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa. |
NSP10/NSP16 Complex (SARS-CoV-2) |
|||
100747-2 | BPS Bioscience | 1 mg | EUR 2500 |
Description: Complex of SARS-CoV-2 nonstructural protein 10 (NSP10), GenBank Accession No. YP_009725306.1, a.a. 1-139(full length), with N-terminal FLAG-tag, MW=16 kDa and SARS-CoV-2 nonstructural protein 16 (NSP16), Genbank Accession No. YP_009725311, a.a. 1-298(full length), with N-terminal His-tag, MW=34 kDa, co-expressed in a HEK293 cell expression system. |
NSP7, His-tag (SARS-CoV-2) |
|||
100829-2 | BPS Bioscience | 1 mg | EUR 2600 |
Description: SARS-CoV-2 nonstructural protein 7 (NSP7), Genbank Accession No.: YP_009742614, a.a. 1-84(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 10 kDa. |
NSP8, His-tag (SARS-CoV-2) |
|||
100830-2 | BPS Bioscience | 1 mg | EUR 2730 |
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa. |
Anti-Nucleocapsid Antibody (SARS-CoV-2 ) |
|||
100861-2 | BPS Bioscience | 100 µg | EUR 420 |
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Nucleocapsid (N) protein. |
ORF9b, GST-Tag (SARS-CoV-2) |
|||
100962-2 | BPS Bioscience | 1 mg | EUR 2720 |
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification. |
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
|||
9119-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
|||
9119-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
|||
9123-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody |
|||
9123-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) S2 Recombinant Protein |
|||
11-184 | ProSci | 0.2 mg | EUR 1212 |
Description: It's been reported that SARS-CoV-2 can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
SARS-CoV-2 (COVID-19) S2 Recombinant Protein |
|||
10-426 | ProSci | 0.1 mg | EUR 651.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Spike Trimer (S1+S2) (BA.2.3.20, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101654-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.3.20 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BA.2.75, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101655-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101656-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant+K444T), His-Tag (SARS-CoV-2) |
|||
101657-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 plus mutation K444T. Thus, it contains all the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BN.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101659-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BN.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (XBB.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101661-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BA.5, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101662-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.5 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BA.4.6, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101664-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.4.6 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BQ.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101665-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BQ.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (BQ.1.1, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101666-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BQ.1.1 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Spike Trimer (S1+S2) (XBB.1.5, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101677-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant XBB.1.5 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag |
|||
E80020 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag |
|||
E80022 | EpiGentek |
|
|
SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag |
|||
E80025 | EpiGentek |
|
|
3CL Protease (SARS-CoV-2) Assay Kit |
|||
79955-2 | BPS Bioscience | 384 rxns. | EUR 1265 |
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. 3CL inhibitor GC376 is also included as an inhibitor control. |
Spike S1, Fc fusion (SARS-CoV-2) |
|||
100688-2 | BPS Bioscience | 50 µg | EUR 505 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa. |
Anti-Spike S1 Antibody (SARS-CoV-2) |
|||
100715-2 | BPS Bioscience | 100 µg | EUR 440 |
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus. |
Spike Trimer (S1+S2) (BA.2.75.2, Omicron Variant+V445P+F490S), His-Tag (SARS-CoV-2) |
|||
101658-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BA.2.75.2 plus mutations V445 and F490S. Thus, it contains all the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-10 | Biovision | 10µg | EUR 187.2 |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-50 | Biovision | 50µg | EUR 661.2 |
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
|||
9123-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody (biotin) |
|||
9123-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [4F10] |
|||
PM-9428-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [4F10] |
|||
PM-9428-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [5E6] |
|||
PM-9429-002mg | ProSci | 0.02 mg | EUR 229.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [5E6] |
|||
PM-9429-01mg | ProSci | 0.1 mg | EUR 594.26 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A6] |
|||
SD9785-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A6] |
|||
SD9785-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1B8] |
|||
SD9787-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1B8] |
|||
SD9787-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1G5] |
|||
SD9789-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1G5] |
|||
SD9789-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A9] |
|||
SD9791-002mg | ProSci | 0.02 mg | EUR 253.22 |
Description: N/A |
SARS-CoV-2 (COVID-19) Spike S2 Antibody [P1A9] |
|||
SD9791-01mg | ProSci | 0.1 mg | EUR 723.62 |
Description: N/A |
Spike Trimer (S1+S2), His-tag (SARS-CoV-2) |
|||
100728-1 | BPS Bioscience | 100 µg | EUR 350 |
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682RRAR685>A, K986P, and V987P mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=139 kDa. |
SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag |
|||
E80027-2 | EpiGentek | 100 ul | EUR 4087.6 |
3CL Protease, Untagged (SARS-CoV-2) Assay Kit |
|||
78042-2 | BPS Bioscience | 384 rxns. | EUR 1210 |
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease sactivity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. |
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
79942-2 | BPS Bioscience | 500 µl x 2 | EUR 4405 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
79981-2 | BPS Bioscience | 500 µl x 2 | EUR 5245 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Spike S1 RBD, His-tag (SARS-CoV-2) |
|||
100687-2 | BPS Bioscience | 100 µg | EUR 520 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa. |
Spike S1 RBD, Fc fusion (SARS-CoV-2) |
|||
100699-2 | BPS Bioscience | 100 µg | EUR 520 |
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
3CL Protease (Mpro), MBP-tag (SARS-CoV-2) |
|||
100707-2 | BPS Bioscience | 1 mg | EUR 2535 |
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), with an N-terminal MBP-tag, expressed in an E. coli expression system, MW=77.5 kDa. |
Nucleocapsid Protein, Avi-His-tag (SARS-CoV-2) |
|||
100778-2 | BPS Bioscience | 1 mg | EUR 2730 |
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
Spike Trimer (S1+S2), His-tag (SARS-CoV) |
|||
100789-1 | BPS Bioscience | 100 µg | EUR 450 |
Description: Severe acute respiratory Coronavirus SARS Coronavirus Spike trimer (S1+S2) (SARS-CoV S protein), Genbank Accession No. AAP13567, a.a. 1-1195(full length), with a C-terminal His-tag, expressed in a HEK293 expression system. MW=136 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
SARS-CoV-2 (COVID-19) Spike Glycoprotein-S2, Recombinant protein |
|||
39-112 | ProSci | 0.05 mg | EUR 1520.7 |
Description: A human infecting coronavirus (viral pneumonia) called 2019 novel coronavirus, 2019-nCoV was found in the fish market at the city of Wuhan, Hubei province of China on December 2019. The 2019-nCoV shares an 87% identity to the 2 bat-derived severe acute respiratory syndrome 2018 SARS-CoV-2 located in Zhoushan of eastern China. 2019-nCoV has an analogous receptor-BD-structure to that of 2018 SARS-CoV, even though there is a.a. diversity so thus the 2019-nCoV might bind to ACE2 receptor protein (angiotensin-converting enzyme 2) in humans. While bats are possibly the host of 2019-nCoV, researchers suspect that animal from the ocean sold at the seafood market was an intermediate host. RSCU analysis proposes that the 2019-nCoV is a recombinant within the viral spike glycoprotein between the bat coronavirus and an unknown coronavirus. |
SARS-CoV-2 (COVID-19) Spike S2 ECD Recombinant Protein |
|||
10-115 | ProSci | 0.1 mg | EUR 651.3 |
Description: SARS-CoV-2 (COVID-19) Spike S2 ECD Recombinant Protein |
Spike Trimer (S1+S2) (D614G), His-tag (SARS-CoV-2) |
|||
100810 | BPS Bioscience | 100 µg | EUR 450 |
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), with 682-685>A, K986P, V987P, and D614G mutations, Genbank Accession No. MN908947, a.a. 1-1213, with a C-terminal His-tag, expressed in a HEK293 expression system. MW=137 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial |
|||
E80028-2 | EpiGentek | 100 ul | EUR 860.2 |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (Luc Reporter) |
|||
78028-2 | BPS Bioscience | 500 µl x 2 | EUR 4510 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Spike (SARS-CoV-2, D614G) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78035-2 | BPS Bioscience | 500 µl x 2 | EUR 5145 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A SARS-CoV-2 variant carrying the spike protein amino acid change D614G has become the most prevalent form in the global pandemic. The SARS-CoV-2 Spike D614G Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike D614G pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ |
Spike S1 RBD, Mouse Fc-fusion (SARS-CoV-2) |
|||
100684-2 | BPS Bioscience | 50 µg | EUR 435 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), also known as novel coronavirus spike S1 and nCoV spike S1, GenBank Accession No. QHD43416.1, a.a. 319-541, with a C-terminal mouse Fc-tag (mFc), expressed in a HEK293 cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 RBD, Avi-His-tag (SARS-CoV-2) |
|||
100696-2 | BPS Bioscience | 1 mg | EUR 3200 |
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 29 kDa. |
Spike S1 RBD-Nucleocapsid Protein Chimera (SARS-CoV-2) |
|||
100938-2 | BPS Bioscience | 50 µg | EUR 555 |
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (Spike S1 RBD), GenBank Accession No. MN908947, a.a. 319-541, fused with HSA to SARS-CoV-2 Nucleocapsid protein (N-protein), GenBank Accession No. QHD43423, a.a 237-419, with C-terminal His-tag, Expressed in CHO cells. MW=130 kDa. |
3CL Protease (B.1.1.529, Omicron Variant), (SARS-CoV-2) |
|||
101328-2 | BPS Bioscience | 1 mg | EUR 2750 |
Description: Purified recombinant SARS-CoV-2 protease 3CL (3C-like protease, also known as MPro) full length encompassing amino acids 1-306 (end). This construct does not contain a tag. The protein corresponds to SARS-CoV-2 variant B.1.1.529 (Omicron Variant), originally discovered in South Africa, and contains mutation P132H. |
Spike Trimer (S1+S2) (BF.7/BA.5.2.6/BF.11, Omicron Variant), His-Tag (SARS-CoV-2) Recombinant |
|||
101663-2 | BPS Bioscience | 100 µg | EUR 625 |
Description: Recombinant SARS-CoV-2 Spike protein in its homotrimeric form, containing S1+S2 subunits. This protein corresponds to SARS-CoV-2 Omicron Variant BF.7/BA.5.2.6/BF.11 and contains the Omicron Spike mutations listed below. The construct also contains a C-terminal His-tag. The recombinant protein was affinity purified. |
3CL Protease (SARS-CoV-1 / SARS-CoV-2) Substrate |
|||
79952-1 | BPS Bioscience | 1 mg | EUR 445 |
Description: Sensitive internally quenched fluorogenic (FRET) substrate for SARS main protease with a Km value of 17 µM and a kcat value of 1.9 s»¹. |
Human CellExp™ Coronavirus Spike Protein (SARS-CoV-2; S2), Recombinant |
|||
P1525-10 | Biovision | 10 µg | EUR 332.4 |
Recombinant SARS-CoV-2 Spike S2 ECD Protein with His-Tag |
|||
E80009-1 | EpiGentek | 100 ul | EUR 518.1 |
Spike Trimer (S1+S2), His-tag, Eu-labeled (SARS-CoV-2) |
|||
100894 | BPS Bioscience | 25 µg | EUR 295 |
Description: Severe acute respiratory Coronavirus Spike trimer (S1+S2), Genbank Accession No. MN908947, a.a. 16-1213, with a with C-terminal His-tag, Eu-labeled, expressed in a HEK293 expression system. MW=139 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
SARS S2 [His] |
|||
DAG1862 | Creative Diagnostics | 500 ug | EUR 3034.8 |
SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag |
|||
E80024-2 | EpiGentek | 1 ml | EUR 4995.1 |
SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion |
|||
E80026-2 | EpiGentek | 50 ul | EUR 823.9 |
Spike (SARS-CoV-2, UK Variant) Pseudotyped Lentivirus (Luc Reporter) |
|||
78112-2 | BPS Bioscience | 500 µl x 2 | EUR 4405 |
Description: The Spike (SARS-CoV-2, UK variant) Pseudotyped Lentivirus were produced with SARS-CoV-2 UK Variant Spike (Genbank Accession #QHD43416.1 with UK variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, UK variant) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 UK variant in a Biosafety Level 2 facility._x000D_ |
Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78637-2 | BPS Bioscience | 500 µl x 2 | EUR 3995 |
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices. |
Spike(SARS-CoV-2) Pseudotyped Lentivirus (Luc-eGFP Dual Reporter) |
|||
79982-2 | BPS Bioscience | 500 µl x 2 | EUR 8110 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_ The SARS-CoV-2 Spike Pseudotyped Lentivirus (Luc-eGFP dual reporter) were produced by replacing the VSV-G fusion glycoprotein with SARS-CoV-2 Spike protein (Genbank Accession #QHD43416.1) as a surrogate viral envelope protein. These pseudovirions also contain a firefly luciferase and eGFP cassette (Luc-P2A-eGFP) driven by a CMV promoter. The luciferase and eGFP are coexpressed under the CMV promoter in the transduced cells. Therefore, the Spike-mediated entry into the target cell can be conveniently measured via luciferase reporter activity or eGFP expression. The SARS-CoV-2 Spike pseudotyped lentivirus can be used in a cellular assay to measure the activity of neutralizing antibody against SARS-CoV-2._x000D_ |
Papain-like Protease (SARS-CoV-2) Assay Kit: Protease Activity |
|||
79995-2 | BPS Bioscience | 384 rxns. | EUR 1240 |
Description: The Papain-like Protease Assay Kit: Protease Activity is designed to measure PLPro activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. |
Spike S1 RBD, Fc-Fusion, Avi-Tag (SARS-CoV-2) |
|||
100698-2 | BPS Bioscience | 1 mg | EUR 2500 |
Description: SARS-CoV-2 Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. MN_908947.1, a.a. 319-541, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 cell expression system. MW=54 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 (16-685), Avi-His-tag (SARS-CoV-2) |
|||
100730-2 | BPS Bioscience | 1 mg | EUR 2720 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685 with a C-terminal Avi-His-tag, expressed in a HEK293 expression system, MW=78 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 RBD (V367F), Avi-His-tag (SARS-CoV-2) |
|||
100769-2 | BPS Bioscience | 1 mg | EUR 2500 |
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
Nucleocapsid Protein, Avi-His-tag, Biotin-Labeled (SARS-CoV-2) |
|||
100779-2 | BPS Bioscience | 50 µg | EUR 435 |
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. This protein is enzymatically biotinylated using Avi-His-Tag™ technology. Biotinylation is confirmed to be ≥90% |
Spike S1 RBD (V483A), Avi-His-tag (SARS-CoV-2) |
|||
100846-2 | BPS Bioscience | 1 mg | EUR 2600 |
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541 with a V367F mutation and a with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
Spike S1 (B.1.351), Avi-His-Tag (SARS-CoV-2) |
|||
100992-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.351 originally identified in South Africa and contains mutations L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6xHis). The recombinant protein is ≥90% pure following affinity purification. |
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
78625-2 | BPS Bioscience | 500 µl x 2 | EUR 4510 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. The Omicron Variant (B.1.1.529 variant) was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1, BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron BA.2 pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2, Omicron Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78626-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of February 2022, Omicron variants have been divided into four distinct sub-lineages: BA.1 (B.1.1.529), BA.1.1, BA.2, and BA.3.The Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 BA.2 Variant Spike (Genbank Accession #QHD43416.1 containing all the BA.2 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the eGFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (BA.2, Omicron Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 BA.2 variant in a Biosafety Level 2 facility.The Spike Omicron pseudovirus has been validated for use with target cells ACE2-HEK293 (which overexpress ACE2; BPS Bioscience #79951).Spike Mutations in BA.2 Variant: T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag |
|||
E80021-2 | EpiGentek | 1 ml | EUR 4276.8 |
SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag |
|||
E80023-2 | EpiGentek | 1 ml | EUR 3934.7 |
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
78142-2 | BPS Bioscience | 500 µl x 2 | EUR 4320 |
Description: The Spike (SARS-CoV-2) (B.1.351) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, A701V) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) (B.1.351) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.351 variant in a Biosafety Level 2 facility._x000D_ |
Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
78143-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: The Spike (K417T, E484K, N501Y) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with mutations K417T, E484K, and N501Y) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2, K417T, E484K, N501Y) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 K417T, E484K, N501Y variant in intact cells using a Biosafety Level 2 facility._x000D_ |
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc Reporter) |
|||
78144-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank #QHD43416.1 with P.1 mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility._x000D_ |
Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78158-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. The United Kingdom (UK) identified a variant called B.1.1.7 with a large number of mutations in the fall of 2020. This variant spreads more easily and quickly than other variants. The Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.1.7 variant Spike (Genbank Accession #QHD43416.1 with B.1.1.7 variant mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP fluorescence. The Spike (B.1.1.7 Variant) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 B.1.1.7 variant in a Biosafety Level 2 facility. |
Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78159-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. In Brazil, a variant called P.1 was first identified in the summer of 2020. This variant has many mutations that may lead to higher transmissibility and infectivity. The Spike (P.1) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Variant Spike (Genbank Accession #QHD43416.1 with P.1 mutations, see below for details) as the envelope glycoproteins instead of the commonly used VSVG. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (P.1) (SARS-CoV-2) pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (P.1) variant using a Biosafety Level 2 facility. |
Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter) |
|||
78160-2 | BPS Bioscience | 500 µl x 2 | EUR 4195 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein and ACE2 may offer protection against the viral infection. A variant called B.1.351 was first identified in the fall of 2020 in the Republic of South Africa. This South African variant, also known as 501Y.V2, has many mutations that may lead to higher transmissibility and infectivity. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus were produced with SARS-CoV-2 B.1.351 Variant Spike (Genbank Accession #QHD43416.1 with B.1.351 mutations; see below for details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the enhanced green fluorescent protein (eGFP) gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be determined via eGFP fluorescence. The Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 (B.1.351) variant in a Biosafety Level 2 facility. |
3CL Protease (B.1.1.529, Omicron Variant) (SARS-CoV-2) Assay Kit |
|||
78350-2 | BPS Bioscience | 384 rxns. | EUR 1315 |
Description: The 3CL Protease (B.1.1.529, Omicron Variant) (SARS-CoV-2) Assay Kit is designed to measure the activity of P132H mutated, Omicron variant 3CL Protease for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps.The 3CL Protease Substrate is an internally quenched 14-mer fluorogenic (FRET) peptide (DABCYL-KTSAVLQSGFRKME-EDANS). When the donor (EDANS) and acceptor (DABCYL) fluorophores are in close proximity, the energy emitted from EDANS is quenched by DABCYL (intact substrate). Upon proteolysis by 3CL, the peptide substrate is cleaved between glutamine and serine to generate the highly fluorescent peptide fragment (SGFRKME-EDANS). The fluorescence intensity increases proportionally to the activity of 3CL. More information on the substrate, including MW and structure, can be found on our website (BPS Bioscience, #79952). |
Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78642-2 | BPS Bioscience | 500 µl x 2 | EUR 3995 |
Description: The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 D614G variant in a Biosafety Level 2 facility.The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells. |
Spike S1-Biotin (SARS-CoV-2): ACE2 TR-FRET Assay Kit |
|||
79949-2 | BPS Bioscience | 384 rxns. | EUR 1265 |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As a first step of the viral replication strategy, the virus attaches to the host cell surface before entering the cell. The Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer some protection against the viral infection._x000D_The SARS-CoV-2 Spike S1:ACE2 TR-FRET Assay is designed to measure the inhibition of the binding between SARS-CoV-2 Spike S1 and human ACE2 in a homogeneous 96 or 384 reaction format. This TR-FRET-based assay requires no time-consuming washing steps, making it especially suitable for high throughput screening applications. The assay procedure is straightforward and simple; the test inhibitor compound is incubated with biotinylated Spike S1, Eu-labeled ACE2, dye-labeled acceptor and an inhibitor for one hour. Then the TR-FRET signal is measured using a fluorescence reader._x000D_ |
Spike S1 (13-665), Fc Fusion, Avi-tag (SARS-CoV-2) |
|||
100678-2 | BPS Bioscience | 1 mg | EUR 3000 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 13-665, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=102 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 RBD, Avi-His-tag, Biotin-labeled (SARS-CoV-2) |
|||
100697-2 | BPS Bioscience | 50 µg | EUR 480 |
Description: SARS-CoV-2 Spike S1 receptor binding domain (RBD), also known as SARS-CoV-2 Spike 1 RBD, novel coronavirus Spike 1 RBD and nCoV Spike 1 RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system and enzymatically biotinylated using Avi-tag™ technology. Biotinylation is confirmed to be ≥90%. MW=28 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation. |
Spike S1 (16-685), Fc Fusion, Avi-tag (SARS-CoV-2) |
|||
100719-2 | BPS Bioscience | 1 mg | EUR 2720 |
Description: Severe acute respiratory Coronavirus 2 Spike Glycoprotein S1 (SARS-CoV-2 Spike S1), GenBank Accession No. QHD43416.1, a.a. 16-685, fused at the C-terminus of the Fc portion of human IgG1, with a C-terminal Avi-tag™, expressed in a HEK293 expression system, MW=104 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation. |
Spike S1 RBD, His-Avi-Tag, Biotin-Labeled (SARS-CoV-2) |
|||
100937-2 | BPS Bioscience | 50 µg | EUR 435 |
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This construct contains a C-terminal His-tag (6xHis) followed by an Avi-Tag. The protein was enzymatically biotinylated using the Avi-Tag™ and affinity purified. |
Spike RBD (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2) |
|||
100977-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.1.7, originally discovered in the United Kingdom, and contains mutation N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification. |
Spike RBD (B.1.351 Variant) Avi-His-Tag (SARS-CoV-2) |
|||
100978-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein, RBD (Receptor Binding Domain) encompassing amino acids 319-541. This protein corresponds to SARS-CoV-2 Variant B.1.351, orignally discovered in South Africa and contains mutations K417N, E484K and N501Y. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification and shows less than 5% aggregation in gel filtration. |
Nucleocapsid Protein (B.1.351 Variant), Avi-His-Tag (SARS-CoV-2) |
|||
100985-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Nucleocapsid protein (N protein), full length, encompassing amino acids 1-419(end). This protein corresponds to SARS-CoV-2 Variant B.1.351 originally discovered in South Africa, and contains mutation T205I. It also contains a C-terminal Avi-Tag™ and a C-terminal His-tag. The recombinant protein is ≥90% pure following high affinity Ni-NTA purification. |
Spike S1 (B.1.1.7 Variant), Avi-His-Tag (SARS-CoV-2) |
|||
101001-2 | BPS Bioscience | 1 mg | EUR 2850 |
Description: Recombinant SARS-CoV-2 Spike protein, S1 subunit encompassing amino acids 16-685. This protein corresponds to SARS-CoV-2 Variant B.1.1.7 identified in the United Kingdom and contains mutations N501Y, A570D, D614G, P681H, and deletions 69-70HV and 144Y. It also contains a C-terminal Avi-Tag™ followed by a C-terminal His-tag (6His). The recombinant protein is ≥90% pure following affinity purification. |